SPOTLIGHT: Senetek inks new rights pact

Senetek of Napa, California, has signed a new agreement giving Valeant Pharmaceuticals expanded distribution rights for Kinetin and exclusive marketing rights to Zeatin in exchange for $37 million in guaranteed royalties over the next five years. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.